عنوان
پدید آورنده
موضوع
رده
کتابخانه
محل استقرار
شماره کتابشناسی ملی
شماره
TLpq2404660144
زبان اثر
زبان متن نوشتاري يا گفتاري و مانند آن
انگلیسی
عنوان و نام پديدآور
عنوان اصلي
The Use of Metformin as Primary Prevention of Major Adverse Cardiac Events in Euglycemic Patients
نام عام مواد
[Thesis]
نام نخستين پديدآور
Campbell, Shannon
نام ساير پديدآوران
LaScalea, Keith
وضعیت نشر و پخش و غیره
نام ناشر، پخش کننده و غيره
Weill Medical College of Cornell University
تاریخ نشرو بخش و غیره
2020
مشخصات ظاهری
نام خاص و کميت اثر
46
یادداشتهای مربوط به پایان نامه ها
جزئيات پايان نامه و نوع درجه آن
M.S.
کسي که مدرک را اعطا کرده
Weill Medical College of Cornell University
امتياز متن
2020
یادداشتهای مربوط به خلاصه یا چکیده
متن يادداشت
Problem: Cardiovascular disease is one of the top causes of mortality worldwide. Currently, there are methods in place that range from dietary modification and exercise to statin therapy for primary and secondary prevention. An alternative therapy for patients who do not yet qualify for statin therapy is needed to minimize the risk of disease. Metformin may be a putative solution for this gap in preventative care. Purpose: The purpose of this study is to evaluate levels of inflammation, central adiposity and overall adverse outcomes following metformin administration. Methods: Following an extensive literature review, the following study design is proposed. The study will recruit patients aged 30-65 years with at least two risk factors of cardiovascular disease. Participants on aspirin or statin therapy will be excluded as well as those with known history of diabetes mellitus type 1 or 2. Participants will start at 250 mg metformin twice a day and their dosage will increase to 500 mg twice daily after the medication is deemed well-tolerated. Outcomes: Participants will be followed every three to every six months for a total of five years. Serologic testing including CRP and IL-6 will be measured each visit. Additionally, weight and waist circumference will be measured. Participants will be assessed for adverse outcomes or other concurrent medical problems. Benefit: An additional method for primary prevention of cardiovascular disease can have a large impact on the health of the population by decreasing morbidity and mortality. Metformin can reduce many of the known factors that predispose individuals to heart disease such as central adiposity and inflammation.
موضوع (اسم عام یاعبارت اسمی عام)
موضوع مستند نشده
Adverse cardiac events
موضوع مستند نشده
Euglycemic patients
موضوع مستند نشده
Health sciences
موضوع مستند نشده
Metformin
نام شخص به منزله سر شناسه - (مسئولیت معنوی درجه اول )
مستند نام اشخاص تاييد نشده
Campbell, Shannon
مستند نام اشخاص تاييد نشده
LaScalea, Keith
دسترسی و محل الکترونیکی
نام الکترونيکي
مطالعه متن کتاب وضعیت انتشار
فرمت انتشار
p
اطلاعات رکورد کتابشناسی
نوع ماده
[Thesis]
کد کاربرگه
276903
اطلاعات دسترسی رکورد
سطح دسترسي
a
تكميل شده
Y
